Basilea Pharmaceutica Ag Stock Shares Owned By Institutions
| BPMUF Stock | USD 52.83 0.00 0.00% |
Basilea Pharmaceutica AG fundamentals help investors to digest information that contributes to Basilea Pharmaceutica's financial success or failures. It also enables traders to predict the movement of Basilea Pink Sheet. The fundamental analysis module provides a way to measure Basilea Pharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Basilea Pharmaceutica pink sheet.
Basilea |
Basilea Pharmaceutica AG Company Shares Owned By Institutions Analysis
Basilea Pharmaceutica's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Basilea Pharmaceutica Shares Owned By Institutions | 29.13 % |
Most of Basilea Pharmaceutica's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Basilea Pharmaceutica AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 29.13% of Basilea Pharmaceutica AG are shares owned by institutions. This is 34.74% lower than that of the Healthcare sector and 38.67% lower than that of the Biotechnology industry. The shares owned by institutions for all United States stocks is 25.71% higher than that of the company.
Basilea Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Basilea Pharmaceutica's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Basilea Pharmaceutica could also be used in its relative valuation, which is a method of valuing Basilea Pharmaceutica by comparing valuation metrics of similar companies.Basilea Pharmaceutica is currently under evaluation in shares owned by institutions category among its peers.
Basilea Fundamentals
| Return On Asset | 0.0261 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 724.26 M | |||
| Shares Outstanding | 11.93 M | |||
| Shares Owned By Insiders | 3.07 % | |||
| Shares Owned By Institutions | 29.13 % | |||
| Price To Earning | 200.00 X | |||
| Price To Sales | 4.09 X | |||
| Revenue | 148.12 M | |||
| Gross Profit | 30.89 M | |||
| EBITDA | 2.11 M | |||
| Net Income | (6.83 M) | |||
| Cash And Equivalents | 140.74 M | |||
| Cash Per Share | 11.89 X | |||
| Total Debt | 94.54 M | |||
| Current Ratio | 1.36 X | |||
| Book Value Per Share | (5.67) X | |||
| Cash Flow From Operations | (32.02 M) | |||
| Earnings Per Share | 0.25 X | |||
| Number Of Employees | 177 | |||
| Beta | 0.88 | |||
| Market Capitalization | 626.06 M | |||
| Total Asset | 247.27 M | |||
| Retained Earnings | (908 M) | |||
| Working Capital | 219 M | |||
| Current Asset | 283 M | |||
| Current Liabilities | 64 M | |||
| Z Score | -0.6 | |||
| Net Asset | 247.27 M |
About Basilea Pharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Basilea Pharmaceutica AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Basilea Pharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Basilea Pharmaceutica AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Basilea Pink Sheet
Basilea Pharmaceutica financial ratios help investors to determine whether Basilea Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Basilea with respect to the benefits of owning Basilea Pharmaceutica security.